Hologic completes sale of blood screening business to Grifols

Hologic has announced the completion of the sale of its blood screening business in a deal worth $1.85 billion (1.48 billion pounds).

The company has transferred ownership of the business to its long-time commercial partner Grifols, a move that will help Hologic to improve its focus on high-growth priority areas, while also significantly increasing its financial flexibility.

Hologic and Grifols have collaborated in the molecular blood screening field since 1998 through their respective predecessor companies, becoming global leaders in the sector.

In addition to intellectual property rights, approximately 175 members of staff – mainly in operations and research and development – have transferred from Hologic to Grifols as part of this transaction.

Hologic's blood screening manufacturing facility in Rancho Bernardo, California has also been sold off, though the company will retain the engineering experts responsible for the Tigris and Panther systems.

Steve MacMillan, Hologic's chairman, president and chief executive officer, said: "We are immensely proud of the contributions we have made to global blood safety over nearly 20 years, and wish our former employees and partner much continued success in the field."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.